A team of researchers have demonstrated a technique that, by measuring the physical properties of individual cells in body fluids, can diagnose cancer with a high degree of accuracy. The technique, which uses a deformability cytometer to analyze individual cells, could reduce the need for more cumbersome diagnostic procedures and the associated costs, while improving accuracy over current methods.
About half of all cancer patients have a mutation in a gene called p53, which allows tumors to survive and continue growing even after chemotherapy severely damages their DNA. A new study from Massachusetts Institute of Technology biologists has found that tumor cells with mutated p53 can be made much more vulnerable to chemotherapy by blocking another gene called MK2.
Researchers at Rice Univ., Baylor College of Medicine and the Univ. of Texas at Austin are working together to create new statistical tools that can find clues about cancer that are hidden like needles in enormous haystacks of raw data.
Purdue Univ. researchers have successfully eliminated the native infection preferences of a Sindbis virus engineered to target and kill cancer cells, a milestone in the manipulation of this promising viral vector. The achievement also demonstrates the ability to use methods of manipulation previously only applied to proteins.
A two-year collaboration between the Chan and the Rocheleau labs at the Institute of Biomaterials & Biomedical Engineering has led to the development of a new microfluidics screening platform that can accurately predict the way nanoparticles will behave in a living body.
Cisplatin is a chemotherapy drug given to more than half of all cancer patients. The drug kills cells very effectively by damaging nuclear DNA, but if tumors become resistant to cisplatin they often grow back. A new study offers a possible way to overcome that resistance. The researchers found that when cisplatin was delivered to cellular structures called mitochondria, DNA in this organelle was damaged, leading to cancer cell death.
Cancer researchers from Rice Univ. have deciphered the operating principles of a genetic switch that cancer cells use to decide when to metastasize and invade other parts of the body. The study found that the on-off switch’s dynamics also allows a third choice that lies somewhere between “on” and “off.” The extra setting both explains previously confusing experimental results and opens the door to new avenues of cancer treatment.
OnTarget Laboratories LLC has teamed with partners in academia to test a novel optical imaging technology developed at Purdue Univ. that could help surgeons see cancer tissue during surgery. The technology is based on the over-expression of specific receptors on solid cancerous tumors and enables illumination of the tumor tissue during surgery.
An aggressive form of breast cancer known as “triple negative” is very difficult to treat: Chemotherapy can shrink such tumors for a while, but in many patients they grow back and gain resistance to the original drugs. To overcome that resistance, chemical engineers have designed nanoparticles that carry the cancer drug doxorubicin, as well as short strands of RNA that can shut off one of the genes that cancer cells use to escape the drug.
The combination of heat, chemotherapeutic drugs and an innovative delivery system based on nanotechnology may significantly improve the treatment of ovarian cancer while reducing side effects from toxic drugs, researchers at Oregon State Univ. report in a new study. The findings, so far done only in a laboratory setting, show that this one-two punch of mild hyperthermia and chemotherapy can kill 95% of ovarian cancer cells.
A colorful wheel developed by Rice Univ. bioengineers to visualize protein interactions has won an international competition for novel strategies to study the roots of breast cancer. The winning BioWheel by the Rice laboratory of bioengineer Amina Qutub was chosen, topping 14 academic and industry participants in the HPN-DREAM Breast Cancer Network Inference Challenge.
Spraying a plant hormone on broccoli—already one of the planet’s most nutritious foods—boosts its cancer-fighting potential, and researchers say they have new insights on how that works. They published their findings, which could help scientists build an even better, more healthful broccoli.
Comparable to nanoscale Navy Seals, Cornell Univ. scientists have merged tiny gold and iron oxide particles to work as a team, then added antibody guides to steer the team through the bloodstream toward colorectal cancer cells. And in a nanosecond, the alloyed allies then kill the bad guys, cancer cells, with absorbed infrared heat.
Researchers at Princeton Univ. have found that microRNAs, which are small bits of genetic material capable of repressing the expression of certain genes, may serve as both therapeutic targets and predictors of metastasis, or a cancer’s spread from its initial site to other parts of the body.
When the "war on cancer" was declared, identifying potential biomarkers that would allow doctors to detect the disease early on was a significant goal. To this day, progress depends on understanding the underlying causes and molecular mechanisms of the disease. In a new study, researchers analyzed the gene-expression profiles of more than 2,000 patients and were able to identify cancer-specific gene signatures for certain cancers.
Researchers at Johns Hopkins Univ. have succeeded in making flattened, football-shaped artificial particles that impersonate immune cells. These football-shaped particles seem to be better than the typical basketball-shaped particles at teaching immune cells to recognize and destroy cancer cells in mice.
When The Cancer Genome Atlas (TCGA) launched its collaborative approach to organ-by-organ genomic analysis of cancers, the brain had both the benefit, and the challenge, of going first. TCGA ganged up on glioblastoma multiforme (GBM), with more than 100 scientists from 14 institutions tracking down the genomic abnormalities that drive GBM. Five years later, TCGA revisited glioblastoma, producing a broader, deeper picture of the drivers.
Gilead Sciences said Wednesday it stopped a late-stage clinical trial of a cancer treatment because it was clear the drug was working. Gilead was studying idelalisib as a treatment for chronic lymphocytic leukemia. The company said an early analysis of data from the study showed that patients who were treated with idelalisib had a longer time before the resumption of disease progression or death.
Chemists at The Scripps Research Institute have devised a new technique for connecting drug molecules to antibodies to make advanced therapies. Antibody-drug conjugates are the basis of new therapies on the market that use the target-recognizing ability of antibodies to deliver drug payloads to specific cell types. The new technique allows drug developers to forge more stable conjugates than are possible with current methods.
A massive data analysis of natural genetic variants in humans and variants in cancer tumors has implicated dozens of mutations in the development of breast and prostate cancer, a Yale Univ.-led team has found. The newly discovered mutations are in regions of DNA that do not code for proteins but instead influence activity of other genes.
Researchers are developing a system that uses tiny magnetic beads to quickly detect rare types of cancer cells circulating in a patient's blood, an advance that could help medical doctors diagnose cancer earlier than now possible and monitor how well a patient is responding to therapy.
A microfluidic chip developed at the Univ. of Michigan is among the best at capturing elusive circulating tumor cells from blood—and it can support the cells' growth for further analysis. The device, believed to be the first to pair these functions, uses the advanced electronics material graphene oxide. In clinics, such a device could one day help doctors diagnose cancers.
A biotech drug from Roche has become the first medicine approved to treat breast cancer before surgery, offering an earlier approach against one of the deadliest forms of the disease. The U.S. Food and Drug Administration (FDA) approved Perjeta for women with a form of early-stage breast cancer who face a high risk of having their cancer spread to other parts of the body.
A “vicious cycle” produces mucus that protects uterine and pancreatic cancer cells and promotes their proliferation, according to researchers at Rice Univ. The researchers offer hope for a therapeutic solution. They found that protein receptors on the surface of cancer cells go into overdrive to stimulate the production of MUC1, which covers the exposed tips of the elongated epithelial cells that coat internal organs to prevent infection.
Government cancer experts say a drug from Roche has shown effectiveness as a new option to treat breast cancer before tumor-removing surgery. The U.S. Food and Drug Administration panel voted 13-0, with one abstention, that the benefits of Perjeta as an initial treatment for breast cancer outweigh its risks.